X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STX-721, Scorpion's highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting EGFR and ERBB2 (HER2) Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.
Lead Product(s): STX-721
Therapeutic Area: Oncology Product Name: STX-721
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
STX-478 is a mutant-selective PI3Kα inhibitor with a potentially best-in-class profile, for the treatment of HR+/HER2- breast cancer and other solid tumors.'
Lead Product(s): STX-478,Fulvestrant
Therapeutic Area: Oncology Product Name: STX-478
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Under the agreement, Scorpion will lead development of STX-721 and Pierre Fabre will lead development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in US, Canada and Japan, and Pierre Fabre will retain commercialization in other territories.
Lead Product(s): STX-721
Therapeutic Area: Oncology Product Name: STX-721
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pierre Fabre
Deal Size: $618.0 million Upfront Cash: $65.0 million
Deal Type: Collaboration April 04, 2023
Details:
STX-241 is the second highly selective EGFR product candidate to emerge from Scorpion’s franchise of next-generation mutant EGFR inhibitors for the treatment of NSCLC.
Lead Product(s): STX-241
Therapeutic Area: Oncology Product Name: STX-241
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
In these studies, STX-478 showed robust anti-tumor activity as both a monotherapy and in combination with standard of care agents in models with kinase or helical domain mutations.
Lead Product(s): STX-478
Therapeutic Area: Oncology Product Name: STX-478
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
STX-478 is a highly selective, allosteric and CNS-penetrant inhibitor of mutant PI3Kα, designed to improve outcomes in patients harboring tumors with prevalent PI3Kα kinase or helical domain mutations.
Lead Product(s): STX-478
Therapeutic Area: Oncology Product Name: STX-478
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
STX-721 is Scorpion’s next-generation, orally delivered, small molecule designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors, a well-known, clinically validated oncogenic driver in non-small cell lung cancer.
Lead Product(s): STX-721
Therapeutic Area: Oncology Product Name: STX-721
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents.
Lead Product(s): STX-721
Therapeutic Area: Oncology Product Name: STX-721
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: $75.0 million
Deal Type: Collaboration January 13, 2022
Details:
Funds to support continued development of Scorpion’s drug hunting engine, which integrates unique capabilities across multiple fields of translational medicine, chemical biology, medicinal chemistry, and data science, as well as the advancement of Scorpion’s growing portfolio.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Boxer Capital
Deal Size: $162.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
